KYMRIAH® (tisagenlecleucel) Mechanism of Action for DLBCL

Mechanism of Action

KYMRIAH MOA Video

Watch this video to learn more about the KYMRIAH^® (tisagenlecleucel) mechanism of action.

About KYMRIAH

KYMRIAH is an individualized therapy that reprograms a patient's own T cells with a chimeric antigen receptor (CAR) containing a 4-1BB costimulatory domain. Upon binding to CD19-expressing cancerous and other B cells, the CAR transmits a signal to promote T cell expansion, activation, target-cell elimination, and persistence of the KYMRIAH T cells. The 4-1BB costimulatory domain is responsible for enhancing the expansion and persistence of KYMRIAH. The KYMRIAH CAR also contains a CD3ζ intracellular signaling domain, which is critical for initiating T cell activation and antitumor activity.¹

Costimulatory domains vary by CARs

4-1BB (KYMRIAH)	CD28
Enhances early expansion and endurance in vitro and in vivo^2,3 Induces central memory T cell differentiation in vitro^3,4: —Enduring protection —Immunosurveillance Improves persistence of the CAR-T cells^1,5	Enhances early and rapid expansion in vitro and in vivo^2,6 Correlated with effector memory T cell differentiation in vitro³: —Immediate protection —Limited long-term persistence

For information about access to KYMRIAH, continue to the next page

Mechanism of Action

Important Safety Information for KYMRIAH^® (tisagenlecleucel)

Indication